← All trials
NCT00000575
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 1991
- Primary completion
- Oct 1, 1999
- Completion date
- Mar 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 1041
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Johns Hopkins UniversityLead sponsor
- Johns Hopkins UniversityOverall official - principal investigator
- University of New MexicoOverall official - principal investigator
- University of California, San DiegoOverall official - principal investigator
- University of Colorado, DenverOverall official - principal investigator
- University of TorontoOverall official - principal investigator
- Asthma, Inc.Overall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Johns Hopkins UniversityReponsible party - principal investigator
- Harvard UniversityOverall official - principal investigator
- Washington University in St. LouisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.